Elena B. Bashnina
Elena B. Bashnina has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Elena Efimovna Petryaykina
Pirogov Russian National Research Medical University
6 shared publications - Irina B. Коstrova
N.M. Kuraev Children’s Republican Clinical Hospital
6 shared publications - Oleg A. Malievskiy
Bashkir State Medical University
6 shared publications - Olga B. Bezlepkina
Endocrinology Research Centre
6 shared publications - Valentina Aleksandrovna Peterkova
Endocrinology Research Centre
6 shared publications - Alexey Vasil'EVich Kiyaev
Ural State Medical University; Regional Children’s Clinical Hospital
5 shared publications
Latest Publications
- Open Access
- 10 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 34-41
Skin reactions in continuous glucose monitoring system users and their influence on adherence to therapy
Introduction. Continuous glucose monitoring (CGM) systems have become an integral component of type 1 diabetes mellitus therapy. However, their widespread adoption has revealed an underestimated problem: skin reactions, which serve as a significant barrier to consistent device usage. Aim. To assess the prevalence and structure of skin reactions associated with CGM use, perform differential diagnosis of dermatitis types, and identify factors influencing patient adherence to this technology. Mat erials and methods. The study included 75 pediatric patients with type 1 diabetes mellitus using CGM systems. Demographic data, duration of device usage, and characteristics of skin manifestations were analyzed. Results. The mean age of participants was 13.1 ± 3.5 years, with a mean CGM usage duration of 7.5 ± 2.7 months. Skin reactions were observed in 18 patients (24.0%). Simple contact dermatitis predominated, affecting 12 patients (66.7% of those with reactions; 16.0% of the total cohort). Allergic contact dermatitis was diagnosed in 6 patients (33.3%; 8.0%). All 12 patients (100%) with simple contact dermatitis continued CGM use despite symptoms. In contrast, adherence in the allergic dermatitis group was significantly lower: 5 out of 6 patients (83.3%) discontinued CGM due to intense pruritus and worsening skin conditions upon reapplication. Only one patient (16.7%) maintained adherence by employing pharmacological treatment and rotating sensor insertion sites. Conclusions. Skin reactions occur in 24.0% of CGM users, confirming the clinical significance of this issue. Simple contact dermatitis is twice as common as allergic contact dermatitis, follows a benign course, and does not compromise treatment adherence. Conversely, allergic contact dermatitis is a key factor leading to technology abandonment. These findings underscore the necessity for timely diagnosis and the development of personalized management strategies to ensure continued access to CGM therapy.
- 10 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 34-41
Open AccessSkin reactions in continuous glucose monitoring system users and their influence on adherence to therapy
Introduction. Continuous glucose monitoring (CGM) systems have become an integral component of type 1 diabetes mellitus therapy. However, their widespread adoption has revealed an underestimated problem: skin reactions, which serve as a significant barrier to consistent device usage. Aim. To assess the prevalence and structure of skin reactions associated with CGM use, perform differential diagnosis of dermatitis types, and identify factors influencing patient adherence to this technology. Mat erials and methods. The study included 75 pediatric patients with type 1 diabetes mellitus using CGM systems. Demographic data, duration of device usage, and characteristics of skin manifestations were analyzed. Results. The mean age of participants was 13.1 ± 3.5 years, with a mean CGM usage duration of 7.5 ± 2.7 months. Skin reactions were observed in 18 patients (24.0%). Simple contact dermatitis predominated, affecting 12 patients (66.7% of those with reactions; 16.0% of the total cohort). Allergic contact dermatitis was diagnosed in 6 patients (33.3%; 8.0%). All 12 patients (100%) with simple contact dermatitis continued CGM use despite symptoms. In contrast, adherence in the allergic dermatitis group was significantly lower: 5 out of 6 patients (83.3%) discontinued CGM due to intense pruritus and worsening skin conditions upon reapplication. Only one patient (16.7%) maintained adherence by employing pharmacological treatment and rotating sensor insertion sites. Conclusions. Skin reactions occur in 24.0% of CGM users, confirming the clinical significance of this issue. Simple contact dermatitis is twice as common as allergic contact dermatitis, follows a benign course, and does not compromise treatment adherence. Conversely, allergic contact dermatitis is a key factor leading to technology abandonment. These findings underscore the necessity for timely diagnosis and the development of personalized management strategies to ensure continued access to CGM therapy.
- Open Access
- 11 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 271-277
Family case of Morris syndrome associated with a novel variant in the androgen receptor gene
Androgen insensitivity syndrome (AIS) is one of the most common causes of disorders of sex development (DSD) with a 46,XY karyotype, caused by pathogenic variants in the androgen receptor gene (AR) leading to complete or partial loss of tissue sensitivity. No specific clinical or laboratory criteria exist for differential diagnosis from other forms of DSD, and diagnosis verification is often complicated by insufficient evidence to assess the pathogenicity of the identified variant. This article is of interest as it describes a familial case of Morris syndrome in two siblings with a 46,XY karyotype, caused by a previously unreported variant c.2342T>C in the AR gene (p.Met781Thr). Both probands had a female phenotype and uterine and vaginal aplasia; DSD was suspected during surgical repair of inguinal hernias, in the sacs of which testicular tissue was found. The diagnosis was confirmed by molecular genetic testing. Laparoscopic gonadectomy was performed, estradiol hormone replacement therapy was initiated, and vitamin D and calcium supplements were prescribed due to osteoporosis. The familial nature of the case allowed the previously unreported AR gene variant to be classified as pathogenic and causative. Thus, an inguinal hernia in a phenotypic girl requires mandatory exclusion of DSD, first of all Morris syndrome, through karyotyping and molecular genetic testing.
- 11 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 271-277
Open AccessFamily case of Morris syndrome associated with a novel variant in the androgen receptor gene
Androgen insensitivity syndrome (AIS) is one of the most common causes of disorders of sex development (DSD) with a 46,XY karyotype, caused by pathogenic variants in the androgen receptor gene (AR) leading to complete or partial loss of tissue sensitivity. No specific clinical or laboratory criteria exist for differential diagnosis from other forms of DSD, and diagnosis verification is often complicated by insufficient evidence to assess the pathogenicity of the identified variant. This article is of interest as it describes a familial case of Morris syndrome in two siblings with a 46,XY karyotype, caused by a previously unreported variant c.2342T>C in the AR gene (p.Met781Thr). Both probands had a female phenotype and uterine and vaginal aplasia; DSD was suspected during surgical repair of inguinal hernias, in the sacs of which testicular tissue was found. The diagnosis was confirmed by molecular genetic testing. Laparoscopic gonadectomy was performed, estradiol hormone replacement therapy was initiated, and vitamin D and calcium supplements were prescribed due to osteoporosis. The familial nature of the case allowed the previously unreported AR gene variant to be classified as pathogenic and causative. Thus, an inguinal hernia in a phenotypic girl requires mandatory exclusion of DSD, first of all Morris syndrome, through karyotyping and molecular genetic testing.
- 19 December 2025
- Published by Bionika Media in Pharmateca
- Vol. 8_2025
The informative value of neonatal TSH in assessing iodine status in the Republic of Karelia
- 19 December 2025
- Published by Bionika Media in Pharmateca
- Vol. 8_2025
The informative value of neonatal TSH in assessing iodine status in the Republic of Karelia
- Open Access
- 10 July 2025
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 16 (2) , 29-39
Ранняя диагностика врожденных эндокринопатий с внедрением расширенного неонатального скрининга
Актуальность. Неонатальный скрининг (НС) на врожденный гипотиреоз (ВГ) и врожденную дисфункцию коры надпочечников (ВДКН) является ключевым звеном в системе оказания медицинской помощи детям с данными эндокринными заболеваниями, который используется во всем мире на протяжении нескольких десятилетий. В России скрининг на ВГ проводится с 1993 года, а с 2006 года — ВДКН. С введением расширения перечня заболеваний, исследуемых в неонатальный период, с 2023 года изменены и условия его проведения. Так, определены более ранние сроки определения гормональных показателей в качестве критериев диагностики ВГ и ВДКН: на 1–2-е сутки жизни для доношенных детей (вместо 3–5 суток) и 7-е сутки для недоношенных детей (вместо 7–14-х суток жизни). Физиологические особенности динамических гормональных изменений новорожденного ребенка в первую неделю жизни могут привести к увеличению ложноположительных результатов и росту ошибочных диагнозов ВГ и ВДКН. Цель. Проведение сравнительного анализа результатов неонатального скрининга на ВГ и ВДКН в 2022 и в 2023 годах у новорожденных детей, рожденных в Санкт-Петербурге, при изменении условий взятия крови для определения тиреотропного гормона (ТТГ) при ВГ и 17-гидроксипрогестерона (17ОНПГ) при ВДКН соответственно. Материалы и методы. Проведено ретроспективное одноцентровое сравнительное исследование. Были проанализированы данные о повышенных результатах в первом сухом пятне при проведении неонатального скрининга на ВГ и ВДКН в 2022 и 2023 годах. Для проведения углубленного статистического анализа сформированы группы новорожденных, родившихся при сроке гестации более 37 полных недель, и весом более 2500 г. Выполнен сравнительный статистический анализ уровня ТТГ и 17ОНПГ в зависимости от срока взятия сухих пятен крови для проведения неонатального скрининга. Результаты. В 2022 году обследовано 51 203 новорожденных, повышение 17ОНПГ в первом сухом пятне зарегистрировано у 213 (0,4%), в 2023 году обследовано 51 306 новорожденных, отклонения от нормы выявлены у 1373 (2,7%) детей. При сравнении уровня 17ОНПГ в первом сухом пятне в 2022 и 2023 годах установлены статистически значимые различия — медиана показателя выше при более раннем взятии сухих пятен крови для обследования. У доношенных новорожденных с массой более 2500 г в 2022 году (n=44 875) медиана уровня 17ОНПГ 7,5 [5,6–9,9] нмоль/л, в 2023 году (n=46360) — 12,4 [9,7–16,0], (р <0,001). При сравнении уровня ТТГ в первом сухом пятне в 2022 и 2023 годах выявлены статистически значимые различия — медиана показателя выше при более раннем взятии сухих пятнен крови для обследования. У доношенных новорожденных массой более 2500 г в 2022 году (n=44 870) медиана уровня ТТГ 2,0 [1,4–2,7] мкМЕ/мл, в 2023 году (n=46 363) — 3,9 [2,9–5,3], (р <0,001). Выводы. Рост числа ложноположительных результатов не сопровождается значимым увеличением ожидаемого количества пациентов с подтвержденным диагнозом. Увеличение количества ложноположительных результатов при исследовании 1-го сухого пятна может быть связано с более ранним взятием крови у новорожденного. Это усложняет лабораторную диагностику, постановку верного диагноза и определяет необходимость возможной коррекции референсных интервалов как 17ОНПГ, так и ТТГ. Background. Neonatal screening (NS) for congenital hypothyroidism (CH) and congenital adrenal hyperplasia (CAH) plays a pivotal role in the early medical care of children with these endocrine disorders and has been utilized globally for several decades. In Russia, screening...
- 10 July 2025
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 16 (2) , 29-39
Open AccessРанняя диагностика врожденных эндокринопатий с внедрением расширенного неонатального скрининга
Актуальность. Неонатальный скрининг (НС) на врожденный гипотиреоз (ВГ) и врожденную дисфункцию коры надпочечников (ВДКН) является ключевым звеном в системе оказания медицинской помощи детям с данными эндокринными заболеваниями, который используется во всем мире на протяжении нескольких десятилетий. В России скрининг на ВГ проводится с 1993 года, а с 2006 года — ВДКН. С введением расширения перечня заболеваний, исследуемых в неонатальный период, с 2023 года изменены и условия его проведения. Так, определены более ранние сроки определения гормональных показателей в качестве критериев диагностики ВГ и ВДКН: на 1–2-е сутки жизни для доношенных детей (вместо 3–5 суток) и 7-е сутки для недоношенных детей (вместо 7–14-х суток жизни). Физиологические особенности динамических гормональных изменений новорожденного ребенка в первую неделю жизни могут привести к увеличению ложноположительных результатов и росту ошибочных диагнозов ВГ и ВДКН. Цель. Проведение сравнительного анализа результатов неонатального скрининга на ВГ и ВДКН в 2022 и в 2023 годах у новорожденных детей, рожденных в Санкт-Петербурге, при изменении условий взятия крови для определения тиреотропного гормона (ТТГ) при ВГ и 17-гидроксипрогестерона (17ОНПГ) при ВДКН соответственно. Материалы и методы. Проведено ретроспективное одноцентровое сравнительное исследование. Были проанализированы данные о повышенных результатах в первом сухом пятне при проведении неонатального скрининга на ВГ и ВДКН в 2022 и 2023 годах. Для проведения углубленного статистического анализа сформированы группы новорожденных, родившихся при сроке гестации более 37 полных недель, и весом более 2500 г. Выполнен сравнительный статистический анализ уровня ТТГ и 17ОНПГ в зависимости от срока взятия сухих пятен крови для проведения неонатального скрининга. Результаты. В 2022 году обследовано 51 203 новорожденных, повышение 17ОНПГ в первом сухом пятне зарегистрировано у 213 (0,4%), в 2023 году обследовано 51 306 новорожденных, отклонения от нормы выявлены у 1373 (2,7%) детей. При сравнении уровня 17ОНПГ в первом сухом пятне в 2022 и 2023 годах установлены статистически значимые различия — медиана показателя выше при более раннем взятии сухих пятен крови для обследования. У доношенных новорожденных с массой более 2500 г в 2022 году (n=44 875) медиана уровня 17ОНПГ 7,5 [5,6–9,9] нмоль/л, в 2023 году (n=46360) — 12,4 [9,7–16,0], (р <0,001). При сравнении уровня ТТГ в первом сухом пятне в 2022 и 2023 годах выявлены статистически значимые различия — медиана показателя выше при более раннем взятии сухих пятнен крови для обследования. У доношенных новорожденных массой более 2500 г в 2022 году (n=44 870) медиана уровня ТТГ 2,0 [1,4–2,7] мкМЕ/мл, в 2023 году (n=46 363) — 3,9 [2,9–5,3], (р <0,001). Выводы. Рост числа ложноположительных результатов не сопровождается значимым увеличением ожидаемого количества пациентов с подтвержденным диагнозом. Увеличение количества ложноположительных результатов при исследовании 1-го сухого пятна может быть связано с более ранним взятием крови у новорожденного. Это усложняет лабораторную диагностику, постановку верного диагноза и определяет необходимость возможной коррекции референсных интервалов как 17ОНПГ, так и ТТГ. Background. Neonatal screening (NS) for congenital hypothyroidism (CH) and congenital adrenal hyperplasia (CAH) plays a pivotal role in the early medical care of children with these endocrine disorders and has been utilized globally for several decades. In Russia, screening...
- 30 December 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 15 (4) , 125-133
One hundred years of endocrinology in Russia. From the history of pediatric endocrinology in Saint Petersburg
Endocrinology, one of the most dynamically developing branches of medicine, has existed as a separate discipline for a little over 100 years. The author of one of the first guidelines on endocrinology in Russia and the founder of the Leningrad School of Clinical Endocrinology was Professor Vasily G. Baranov (1899–1988). In 1926, an endocrinology department was opened at the Department of Therapy of the Leningrad State Institute for Advanced Medical Training under the leadership of Vasily Gavrilovich. Later, in 1963, Professor V.G. Baranov founded the Department of Endocrinology at this educational institution, which currently bears the name of the scientist. V.G. Baranov paid special attention to the issues of endocrine diseases in childhood. Together with academician A.F. Tur, he initiated the creation of an endocrinological service in pediatrics. It was only in 1998 that a new specialty “pediatric endocrinology” was added to the already existing training programs for doctors in the specialty “endocrinology”, opened by order of the Ministry of Health of the Russian Federation. However, the development and formation of pediatric endocrinology as a separate medical discipline took place before official recognition. A special role in the history of this formation belongs to the doctors of St. Petersburg.
- 30 December 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 15 (4) , 125-133
One hundred years of endocrinology in Russia. From the history of pediatric endocrinology in Saint Petersburg
Endocrinology, one of the most dynamically developing branches of medicine, has existed as a separate discipline for a little over 100 years. The author of one of the first guidelines on endocrinology in Russia and the founder of the Leningrad School of Clinical Endocrinology was Professor Vasily G. Baranov (1899–1988). In 1926, an endocrinology department was opened at the Department of Therapy of the Leningrad State Institute for Advanced Medical Training under the leadership of Vasily Gavrilovich. Later, in 1963, Professor V.G. Baranov founded the Department of Endocrinology at this educational institution, which currently bears the name of the scientist. V.G. Baranov paid special attention to the issues of endocrine diseases in childhood. Together with academician A.F. Tur, he initiated the creation of an endocrinological service in pediatrics. It was only in 1998 that a new specialty “pediatric endocrinology” was added to the already existing training programs for doctors in the specialty “endocrinology”, opened by order of the Ministry of Health of the Russian Federation. However, the development and formation of pediatric endocrinology as a separate medical discipline took place before official recognition. A special role in the history of this formation belongs to the doctors of St. Petersburg.
- Open Access
- 17 September 2024
- Published by Endocrinology Research Centre in Clinical and experimental thyroidology
- Vol. 20 (2) , 69-83
Clinical guidelines “Thyroiditis in Children”
Thyroiditis in children are important issues of pediatric endocrinology due to their widespread occurrence. They differ in etiology, pathogenesis, and their clinical manifestations. Updated clinical guidelines in 2024 are the main working tool of physicians. They briefly and structurally present the main information about epidemiology and modern classification of thyroiditis, methods of diagnosis and treatment based on the principles of evidence-based medicine.
- 17 September 2024
- Published by Endocrinology Research Centre in Clinical and experimental thyroidology
- Vol. 20 (2) , 69-83
Open AccessClinical guidelines “Thyroiditis in Children”
Thyroiditis in children are important issues of pediatric endocrinology due to their widespread occurrence. They differ in etiology, pathogenesis, and their clinical manifestations. Updated clinical guidelines in 2024 are the main working tool of physicians. They briefly and structurally present the main information about epidemiology and modern classification of thyroiditis, methods of diagnosis and treatment based on the principles of evidence-based medicine.
- Open Access
- 17 September 2024
- Published by Endocrinology Research Centre in Clinical and experimental thyroidology
- Vol. 20 (2) , 48-68
Clinical guidelines “Congenital hypothyroidism”
Congenital hypothyroidism (CH) is an important issue of pediatric endocrinology. Early detection of this disease and timely initiation of treatment can prevent the development of severe mental retardation. Neonatal screening for CH in Russian Federation has been conducted since 1993. Updated in 2024 clinical guidelines are the main tool of a physicians. They briefly and structurally present main information about congenital hypothyroidism, its epidemiology and modern classification, methods of diagnosis and treatment, based on the principles of evidence-based medicine.
- 17 September 2024
- Published by Endocrinology Research Centre in Clinical and experimental thyroidology
- Vol. 20 (2) , 48-68
Open AccessClinical guidelines “Congenital hypothyroidism”
Congenital hypothyroidism (CH) is an important issue of pediatric endocrinology. Early detection of this disease and timely initiation of treatment can prevent the development of severe mental retardation. Neonatal screening for CH in Russian Federation has been conducted since 1993. Updated in 2024 clinical guidelines are the main tool of a physicians. They briefly and structurally present main information about congenital hypothyroidism, its epidemiology and modern classification, methods of diagnosis and treatment, based on the principles of evidence-based medicine.
- Open Access
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 91-101
Heritable TP53-related cancer syndrome and medulloblastoma in children: diagnostic and screening issues
Today, the contribution of hereditary tumor syndromes to the development of cancer in children is obvious, which determines the need for screening programs and selection of the most effective methods of anticancer therapy. One of the most aggressive hereditary tumor syndromes is heritable TP53-related cancer syndrome (hTP53rc, formerly known as Li–Fraumeni syndrome), characterized by a high risk, early onset and recurrent cases of malignant neoplasms in one patient. The article describes current data on hTP53rc syndrome and the features of its clinical course, and provides international recommendations for monitoring and cancer screening in pediatric patients with hTP53rc syndrome. As a clinical observation, we present an analysis of the registry of patients with relapsed and refractory forms of medulloblastoma (n = 241) with the assessment of its incidence in cases of germline mutations in the TP53 gene with the description of their medical history and the influence of this genetic event on the outcomes. The results of our study, as well as data from international literature, indicate unfavorable prognosis in tumors, including medulloblastoma, in patients with hTP53rc syndrome, however, such factors as early screening, surveillance and early and adequate therapy can help to increase their life expectancy. The study was approved by the Independent Ethics Committee and the Scientific Council of the Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation.
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 91-101
Open AccessHeritable TP53-related cancer syndrome and medulloblastoma in children: diagnostic and screening issues
Today, the contribution of hereditary tumor syndromes to the development of cancer in children is obvious, which determines the need for screening programs and selection of the most effective methods of anticancer therapy. One of the most aggressive hereditary tumor syndromes is heritable TP53-related cancer syndrome (hTP53rc, formerly known as Li–Fraumeni syndrome), characterized by a high risk, early onset and recurrent cases of malignant neoplasms in one patient. The article describes current data on hTP53rc syndrome and the features of its clinical course, and provides international recommendations for monitoring and cancer screening in pediatric patients with hTP53rc syndrome. As a clinical observation, we present an analysis of the registry of patients with relapsed and refractory forms of medulloblastoma (n = 241) with the assessment of its incidence in cases of germline mutations in the TP53 gene with the description of their medical history and the influence of this genetic event on the outcomes. The results of our study, as well as data from international literature, indicate unfavorable prognosis in tumors, including medulloblastoma, in patients with hTP53rc syndrome, however, such factors as early screening, surveillance and early and adequate therapy can help to increase their life expectancy. The study was approved by the Independent Ethics Committee and the Scientific Council of the Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation.
- Open Access
- 12 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 275-284
Multidisciplinary monitoring in pediatric patients with medulloblastoma by primary care physician
Diagnostic and treatment facilities in pediatric oncology have reached a very technological advances in a short period of time, contributing to increased relapse-free and overall survival rates. Obviously, the key factors are the improvement of diagnostic and screening programs, anticancer and concomitant therapy, including personification of clinical guidelines for monitoring and correction of early and late complications in time. Issues regarding the quality of life of patients, including social, psychological rehabilitation and aspects of reproductive potential, are becoming highly actual. The critical importance is that an informed multidisciplinary team of specialists at all stages of anticancer treatment should be involved. This article presents the main algorithms and the most significant issues for pediatricians in the diagnosis and supervision of patients with an oncological diagnosis, using the example of medulloblastoma, as the most common malignant tumor of the central nervous system in children. The proposed recommendations are based on a retrospective analysis of pediatric patients with relapsed and refractory forms of medulloblastoma (n = 270) who received antitumor therapy in the period from 07/01/1993 to 07/01/2023, as well as international clinical data.
- 12 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 275-284
Open AccessMultidisciplinary monitoring in pediatric patients with medulloblastoma by primary care physician
Diagnostic and treatment facilities in pediatric oncology have reached a very technological advances in a short period of time, contributing to increased relapse-free and overall survival rates. Obviously, the key factors are the improvement of diagnostic and screening programs, anticancer and concomitant therapy, including personification of clinical guidelines for monitoring and correction of early and late complications in time. Issues regarding the quality of life of patients, including social, psychological rehabilitation and aspects of reproductive potential, are becoming highly actual. The critical importance is that an informed multidisciplinary team of specialists at all stages of anticancer treatment should be involved. This article presents the main algorithms and the most significant issues for pediatricians in the diagnosis and supervision of patients with an oncological diagnosis, using the example of medulloblastoma, as the most common malignant tumor of the central nervous system in children. The proposed recommendations are based on a retrospective analysis of pediatric patients with relapsed and refractory forms of medulloblastoma (n = 270) who received antitumor therapy in the period from 07/01/1993 to 07/01/2023, as well as international clinical data.
- Open Access
- 22 September 2023
- Published by Russian Society of Immunology in Russian Journal of Immunology
- Vol. 26 (4) , 553-558
Indices of cellular and humoral immunity in a patient with a history of central precocious puberty in anamnesis
The etiology of precocious puberty includes organic anomalies, genetic mutations, but the primary cause remains unclear in the vast majority of cases. Gonadotropin-releasing hormone (GRH) agonists are used as a treatment of gonadotropin-dependent precocious puberty. Blocking the secretion of gonadotropin-releasing hormone, these drugs stop the premature development of sexual features, prevent premature closure of ossification zones, thereby increasing the child’s expected adult height. The interest in the effects of this group of drugs beyond the hypothalamic-pituitary-gonadal axis has been recently increased. A series of clinical cases have been reported on the development of autoimmune diseases, e.g., autoimmune thyroiditis, Graves disease and type 1 diabetes. The article presents a clinical observation of a patient with central form of premature development who exhibited satisfactory response to treatment with a GRH agonist drug. Further follow-up did not show any reproductive dysfunction. Upon immunological examination, a disturbance was revealed only in the cellular component of immunity. An increased metabolic activity of neutrophils was found, thus, probably, indicating a nonspecific inflammatory process. The levels of immunoglobulins A, M, G matched the reference values. Thus, the therapy with a drug from the group of GRH agonists was effective and safe in terms of influencing the patient’s immune system. The role of hormonal disorders and effects of GRH agonists on the development of immunopathological conditions require further research.
- 22 September 2023
- Published by Russian Society of Immunology in Russian Journal of Immunology
- Vol. 26 (4) , 553-558
Open AccessIndices of cellular and humoral immunity in a patient with a history of central precocious puberty in anamnesis
The etiology of precocious puberty includes organic anomalies, genetic mutations, but the primary cause remains unclear in the vast majority of cases. Gonadotropin-releasing hormone (GRH) agonists are used as a treatment of gonadotropin-dependent precocious puberty. Blocking the secretion of gonadotropin-releasing hormone, these drugs stop the premature development of sexual features, prevent premature closure of ossification zones, thereby increasing the child’s expected adult height. The interest in the effects of this group of drugs beyond the hypothalamic-pituitary-gonadal axis has been recently increased. A series of clinical cases have been reported on the development of autoimmune diseases, e.g., autoimmune thyroiditis, Graves disease and type 1 diabetes. The article presents a clinical observation of a patient with central form of premature development who exhibited satisfactory response to treatment with a GRH agonist drug. Further follow-up did not show any reproductive dysfunction. Upon immunological examination, a disturbance was revealed only in the cellular component of immunity. An increased metabolic activity of neutrophils was found, thus, probably, indicating a nonspecific inflammatory process. The levels of immunoglobulins A, M, G matched the reference values. Thus, the therapy with a drug from the group of GRH agonists was effective and safe in terms of influencing the patient’s immune system. The role of hormonal disorders and effects of GRH agonists on the development of immunopathological conditions require further research.